Efficacy Investigated for Electrochemiluminescence Immunoassay
By LabMedica International staff writers Posted on 20 Mar 2019 |
Image: The cobas e 602 integrates immunoassay and clinical chemistry testing on a single platform (Photo courtesy of Roche).
Syphilis caused by Treponema pallidum is a chronic bacterial infection. T. pallidum cannot be cultured in vitro, and new molecular tests for syphilis are unlikely to replace serology in the short term because they are fairly expensive and require sophisticated equipment.
Antibody detection by non-treponemal and treponemal tests is still regarded as the mainstay for diagnosing syphilis and monitoring treatments. Treponemal tests detect antibodies for treponemal antigens. There are many treponemal tests, such as the fluorescent treponemal antibody absorption (FTA-ABS) test, IgG immunoblot test for T. pallidum, enzyme immunoassay (EIA), and chemiluminescence immunoassay (CLIA).
Scientists at the Sungkyunkwan University School of Medicine (Seoul, Republic of Korea) collected samples from 4,771 subjects included in a study. They performed rapid plasma reagin (RPR), electrochemiluminescence immunoassay (ECLIA), and Treponema pallidum particle agglutination (TPPA) according to these three algorithms. The fluorescent treponemal antibody absorbed (FTA-ABS) test was additionally applied for discordant cases between the RPR and ECLIA results. The FTA-ABS results and the consensus of three algorithms were considered a gold standard.
The non-treponemal test, a quantitative RPR, the Mediace rapid plasma reagin test was performed on the Roche P800. The treponemal test, the Roche Diagnostics’ Elecsys Syphilis assay, which is an automated ECLIA, was performed using the Roche e602 platform and interpreted according to 1.0 cutoff index (COI). The automated ECLIA simultaneously detects anti-treponemal IgG and IgM antibodies using recombinant TP antigens such as TpN15, TpN17, and TpN47. The FTA-ABS IgG and IgM were also tested in the specimens showing discordance among the RPR, ECLIA, and TPPA results for confirmation.
The team reported that a total of 208 subjects were diagnosed with syphilis. The traditional algorithm had a sensitivity of 25.96%, specificity of 100%, and accuracy of 96.8%. Both the reverse and European Centre for Disease Prevention and Control (ECDC) algorithms showed the same diagnostic performance, sensitivity of 95.2%, specificity of 99.96%, and accuracy of 99.75%. The agreements between the traditional algorithm and the other algorithms were 96.9% with a kappa value of 0.415.
The authors concluded that their study indicated that the reverse or ECDC algorithm using the ECLIA as a first-line screening test and the TPPA as a second treponemal test could detect more cases of missed serodiagnosis by the traditional algorithm. The reverse algorithm could contribute to the appropriate serodiagnosis of syphilis with superior diagnostic performance. The study was published in the March 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Sungkyunkwan University School of Medicine
Antibody detection by non-treponemal and treponemal tests is still regarded as the mainstay for diagnosing syphilis and monitoring treatments. Treponemal tests detect antibodies for treponemal antigens. There are many treponemal tests, such as the fluorescent treponemal antibody absorption (FTA-ABS) test, IgG immunoblot test for T. pallidum, enzyme immunoassay (EIA), and chemiluminescence immunoassay (CLIA).
Scientists at the Sungkyunkwan University School of Medicine (Seoul, Republic of Korea) collected samples from 4,771 subjects included in a study. They performed rapid plasma reagin (RPR), electrochemiluminescence immunoassay (ECLIA), and Treponema pallidum particle agglutination (TPPA) according to these three algorithms. The fluorescent treponemal antibody absorbed (FTA-ABS) test was additionally applied for discordant cases between the RPR and ECLIA results. The FTA-ABS results and the consensus of three algorithms were considered a gold standard.
The non-treponemal test, a quantitative RPR, the Mediace rapid plasma reagin test was performed on the Roche P800. The treponemal test, the Roche Diagnostics’ Elecsys Syphilis assay, which is an automated ECLIA, was performed using the Roche e602 platform and interpreted according to 1.0 cutoff index (COI). The automated ECLIA simultaneously detects anti-treponemal IgG and IgM antibodies using recombinant TP antigens such as TpN15, TpN17, and TpN47. The FTA-ABS IgG and IgM were also tested in the specimens showing discordance among the RPR, ECLIA, and TPPA results for confirmation.
The team reported that a total of 208 subjects were diagnosed with syphilis. The traditional algorithm had a sensitivity of 25.96%, specificity of 100%, and accuracy of 96.8%. Both the reverse and European Centre for Disease Prevention and Control (ECDC) algorithms showed the same diagnostic performance, sensitivity of 95.2%, specificity of 99.96%, and accuracy of 99.75%. The agreements between the traditional algorithm and the other algorithms were 96.9% with a kappa value of 0.415.
The authors concluded that their study indicated that the reverse or ECDC algorithm using the ECLIA as a first-line screening test and the TPPA as a second treponemal test could detect more cases of missed serodiagnosis by the traditional algorithm. The reverse algorithm could contribute to the appropriate serodiagnosis of syphilis with superior diagnostic performance. The study was published in the March 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Sungkyunkwan University School of Medicine
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA